Abstract

Introduction: The underlying molecular mechanisms of parotid gland carcinomas (PGC) are still unknown. Knowledge about the tumor-driving signaling pathways is necessary either for diagnostics or developing new therapeutic options in this heterogeneous and rare entity.Material and Methods: 94 matching RNA formalin-fixed and paraffin-embedded tissue samples from PGC and the corresponding non-tumor area, RNA quality and quantity were sufficient for gene expression profiling of 770 genes using the NanoString's nCounter technology. Oncogenic and tumor suppressor genes were examined in the three common PGC tumor entities: adenoid cystic carcinoma (ACC), adenocarcinoma NOS (AC-NOS), and mucoepidermoid carcinoma (MEC).Results: Expression profiling and subsequent hierarchical cluster analysis clearly differentiated between non-tumor gland tissue samples and PGC. In addition expression pattern of all three entities differed. The extensive pathway analysis proved a prominent dysregulation of the Wnt signaling pathway in the three PGC entities. Moreover, transcript upstream analysis demonstrated a pronounced activation of the PI3K pathway in ACC and MEC.Discussion: Our findings revealed divergent molecular expression profiles in MEC, ACC and AC-NOS that are presently studied for their potential application in PGC diagnostics. Importantly, identification of Wnt and PI3K signaling in PGC revealed novel options of PGC therapy.

Highlights

  • The underlying molecular mechanisms of parotid gland carcinomas (PGC) are still unknown

  • Our findings revealed divergent molecular expression profiles in mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma (ACC) and adenocarcinoma NOS (AC-NOS) that are presently studied for their potential application in PGC diagnostics

  • Salivary gland carcinomas account for 1–5% of all head and neck tumors worldwide and, according to the World Health Organization (WHO), can be divided into a total of 22 subgroups [1,2,3]

Read more

Summary

Introduction

The underlying molecular mechanisms of parotid gland carcinomas (PGC) are still unknown. Salivary gland carcinomas account for 1–5% of all head and neck tumors worldwide and, according to the World Health Organization (WHO), can be divided into a total of 22 subgroups [1,2,3]. Despite their lower incidence compared to other carcinomas, they represent a scientifically interesting and little-researched tumor group to date due to their diversity of entities. The anatomical location and the potential local spreading pattern of salivary gland cancer (SGC)—especially the parotid gland (PGC)—make these tumors, on the one hand, surgically demanding, and on the other the psychosocial role for the patient quite vital, given that the surgery may involve extensive cosmetic changes to the patient’s face. There are only limited studies on systemic therapy concepts that could be considered in palliative situations [6,7,8]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.